Bayer’s Strategic Pivot: UK Approval for Cancer Drug Marks Critical Step

Bayer faces a period of significant transition as declining revenues from its former blockbuster drugs compel urgent strategic action. The company is increasingly relying on its oncology pipeline to navigate a looming “patent cliff,” and a recent regulatory decision in the United Kingdom provides a tangible milestone in this crucial corporate overhaul.

On April 1, 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for the lung cancer drug Sevabertinib, to be branded as Hyrnuo. This therapy is indicated for adult patients with advanced non-small cell lung cancer whose tumors harbor specific HER2 mutations. Clinical efficacy data for this protein kinase inhibitor is robust, demonstrating a positive response rate in 71% of pre-treated patients. This UK authorization follows an accelerated approval already granted by the U.S. Food and Drug Administration (FDA) in November 2025.

Addressing a Revenue Shortfall

These regulatory successes are strategically vital for the Leverkusen-based conglomerate. Bayer must offset severe revenue losses from its mature pharmaceutical products. In 2025, sales for the blood thinner Xarelto alone plummeted by 33% to €2.3 billion. Management anticipates a further decline of up to 40% for the current year. The eye medication Eylea is also ceding substantial market ground.

Should investors sell immediately? Or is it worth buying Bayer?

New, patent-protected therapies like Sevabertinib are central to bridging this revenue gap in the medium term. At a recent Pharma Media Day event in Berlin, divisional head Stefan Oelrich reaffirmed the goal of returning to a stable growth trajectory from 2027 onward. By 2030, Bayer is targeting an operating margin of 30%, a notable increase from the 25.4% recorded last year. The lung cancer treatment has gained additional momentum through the “Breakthrough Therapy” designation awarded by regulatory authorities in both the United States and China for its use as a first-line treatment.

A Pivotal Spring Calendar

Beyond operational developments in the pharmaceuticals division, shareholders are focusing on several key events scheduled for the coming weeks:

• April 27, 2026: Oral arguments commence before the U.S. Supreme Court concerning the Roundup glyphosate litigation.
• May 12, 2026: Publication of the company’s financial results for the first quarter.
• April 24, 2026: The virtual Annual Stockholders’ Meeting, featuring a vote on the proposed dividend of €0.11 per share.

The MHRA’s approval of Sevabertinib represents a measurable step forward in building Bayer’s new oncology portfolio. The next fundamental test for the corporation arrives at the end of April, when the U.S. Supreme Court begins hearings on the glyphosate matter, followed shortly by management’s release of the first-quarter operational figures.